Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High at $3.40

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as $3.40 and last traded at $3.12, with a volume of 2204764 shares trading hands. The stock had previously closed at $3.12.

Analyst Upgrades and Downgrades

ESPR has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Bank of America downgraded shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, January 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Esperion Therapeutics presently has an average rating of "Hold" and an average target price of $9.33.

Esperion Therapeutics Stock Performance

The stock's fifty day moving average price is $2.46 and its two-hundred day moving average price is $1.86. The company has a market cap of $575.51 million, a P/E ratio of -1.47 and a beta of 0.84.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the company posted ($0.76) EPS. On average, equities research analysts forecast that Esperion Therapeutics, Inc. will post -0.8 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its stake in Esperion Therapeutics by 30.0% in the 2nd quarter. FMR LLC now owns 8,669 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 2,003 shares during the last quarter. Private Portfolio Partners LLC bought a new position in Esperion Therapeutics in the 4th quarter valued at approximately $30,000. Principal Financial Group Inc. bought a new position in Esperion Therapeutics in the 1st quarter valued at approximately $49,000. Amalgamated Bank lifted its stake in Esperion Therapeutics by 18.6% in the 4th quarter. Amalgamated Bank now owns 12,490 shares of the biopharmaceutical company's stock valued at $78,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Invesco Ltd. bought a new position in Esperion Therapeutics in the 1st quarter valued at approximately $65,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.